Dynamic Hyperinflation and Tiotropium

Completed · Phase 4 · Has a placebo group

Conditions studied: COPD

In brief

We will detect dynamic hyperinflation (DH) in 40 COPD (chronic obstructive pulmonary disease) patients with moderately severe disease using metronome paced hyperventilation (MPH) with inspiratory capacity as the primary end point. Hypothesis: Is tiotropium capable of lung volume protecting inspiratory capacity from MPH induced DH vs placebo in a randomized crossover double blinded study.

Key facts

Study ID

NCT00569270

Run by

Gelb, Arthur F., M.D.

People needed

30

Starts

2006-10-01

Expected to finish

2009-03-01

Last updated by the study team

2019-08-20

Who can join

Age: 40 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Moderately severe COPD patients age 40-85 yr with post 180ug albuterol FEV 1 between 60 and 79% predicted and FEV 1/FVC < 70%.
• Smoking history > 10 pack yr.
• Clinically stable X 6 weeks.
• No oxygen usage.

You may not qualify if…

• History of asthma
• Clinically unstable
• Any other significant medical problem precluding full cooperation for study

Where it is running

• Arthur F Gelb MD — Lakewood, California, United States
• Noe Zamel MD — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.